Soluble urokinase plasminogen activator receptor is a prognostic biomarker in decompensated cirrhosis - PubMed
3 days ago
- #Biomarker
- #Cirrhosis
- #Inflammation
- Soluble urokinase plasminogen activator receptor (suPAR) is identified as a prognostic biomarker in decompensated cirrhosis.
- SuPAR levels correlate with disease severity markers, including creatinine, bilirubin, albumin, and MELD score.
- Elevated suPAR levels (≥14.0 ng/ml) independently predict 90-day mortality in decompensated cirrhosis.
- The study includes validation across two independent cohorts, confirming suPAR's predictive value for 28-day and 90-day mortality.
- Single-cell RNA sequencing reveals increased PLAUR expression in monocytes, macrophages, and dendritic cells in HBV-induced cirrhosis.
- SuPAR reflects systemic and liver-specific inflammation, making it a potential biomarker for disease progression and adverse outcomes.
- The findings suggest suPAR could complement established scoring systems like MELD for personalized treatment in advanced chronic liver disease.